Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Short Interest Down 53.1% in February

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) was the target of a significant drop in short interest during the month of February. As of February 28th, there was short interest totalling 12,800 shares, a drop of 53.1% from the February 13th total of 27,300 shares. Currently, 2.0% of the company’s shares are sold short. Based on an average daily volume of 41,400 shares, the short-interest ratio is presently 0.3 days.

Titan Pharmaceuticals Stock Up 2.8 %

NASDAQ TTNP traded up $0.10 during trading on Friday, hitting $3.69. The stock had a trading volume of 25,783 shares, compared to its average volume of 136,214. Titan Pharmaceuticals has a one year low of $3.03 and a one year high of $14.80. The stock has a 50 day simple moving average of $3.58 and a 200 day simple moving average of $4.18.

Titan Pharmaceuticals (NASDAQ:TTNP) last posted its quarterly earnings results on Friday, January 3rd. The specialty pharmaceutical company reported ($0.83) earnings per share for the quarter.

Analyst Upgrades and Downgrades

Separately, StockNews.com started coverage on shares of Titan Pharmaceuticals in a research note on Sunday, March 9th. They issued a “sell” rating for the company.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.